These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2939794)

  • 21. Absolute oral bioavailability of ciprofloxacin.
    Drusano GL; Standiford HC; Plaisance K; Forrest A; Leslie J; Caldwell J
    Antimicrob Agents Chemother; 1986 Sep; 30(3):444-6. PubMed ID: 3777908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis.
    Bender SW; Dalhoff A; Shah PM; Strehl R; Posselt HG
    Infection; 1986; 14(1):17-21. PubMed ID: 2937737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models.
    Dudley MN; Ericson J; Zinner SH
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1782-6. PubMed ID: 3435125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
    Boelaert J; Valcke Y; Schurgers M; Daneels R; Rosseneu M; Rosseel MT; Bogaert MG
    J Antimicrob Chemother; 1985 Jul; 16(1):87-93. PubMed ID: 2931415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciprofloxacin pharmacokinetics in critically ill trauma patients.
    Yuen GJ; Drusano GL; Plaisance K; Forrest A; Caplan ES
    Am J Med; 1989 Nov; 87(5A):70S-75S. PubMed ID: 2589390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.
    Bergan T; Thorsteinsson SB; Solberg R; Bjornskau L; Kolstad IM; Johnsen S
    Am J Med; 1987 Apr; 82(4A):97-102. PubMed ID: 3578334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of three oral formulations of ciprofloxacin.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Smith AL
    Antimicrob Agents Chemother; 1985 Jul; 28(1):74-7. PubMed ID: 2931047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.
    Ball AP; Fox C; Ball ME; Brown IR; Willis JV
    J Antimicrob Chemother; 1986 May; 17(5):629-35. PubMed ID: 2941402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple-dose ciprofloxacin kinetics in normal subjects.
    Aronoff GE; Kenner CH; Sloan RS; Pottratz ST
    Clin Pharmacol Ther; 1984 Sep; 36(3):384-8. PubMed ID: 6467798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.
    Lenfant B; Namour F; Logeais C; Coussediere D; Rivault O; Bryskier A; Surjus A
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2037-41. PubMed ID: 8540712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.
    Leighton A; Gottlieb AB; Dorr MB; Jabes D; Mosconi G; VanSaders C; Mroszczak EJ; Campbell KC; Kelly E
    Antimicrob Agents Chemother; 2004 Mar; 48(3):940-5. PubMed ID: 14982787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.
    Barriere SL; Kaatz GW; Schaberg DR; Fekety R
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1075-8. PubMed ID: 3662471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of ciprofloxacin in elderly subjects.
    LeBel M; Barbeau G; Bergeron MG; Roy D; Vallée F
    Pharmacotherapy; 1986; 6(2):87-91. PubMed ID: 2940518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofloxacin pharmacokinetics in burn patients.
    Garrelts JC; Jost G; Kowalsky SF; Krol GJ; Lettieri JT
    Antimicrob Agents Chemother; 1996 May; 40(5):1153-6. PubMed ID: 8723457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.